Connect with us


Coronavirus vaccine: what we know so far – a comprehensive guide by academic experts –



PHOTO: Wikimedia Commons

Since the early days of the pandemic, attention has focused on producing a vaccine for COVID-19. With one, it’s hoped it will be able to suppress the virus without relying purely on economically challenging control measures. Without one, the world will probably have to live with COVID-19 as an endemic disease. It’s unlikely the coronavirus will naturally burn itself out.

With so much at stake, it’s not surprising that COVID-19 vaccines have become both a public and political obsession. The good news is that making one is possible: the virus has the right characteristics to be fended off with a vaccine, and the economic incentive exists to get one (or indeed several) developed.

But we need to be patient. Creating a new medicine requires a large amount of thought and scrutiny to make sure what’s produced is safe and effective. Researchers must be careful not to allow the pressure and allure of creating a vaccine quickly to undermine the integrity of their work. The upshot may be that we don’t have a highly effective vaccine against COVID-19 for some time.

Here, authors from across The Conversation outline what we know so far. Drawing upon their expertise, they explain how a COVID-19 vaccine will work, the progress a leading vaccine (developed by the University of Oxford with AstraZeneca) is making, and what challenges there will be to manufacturing and rolling a vaccine out when ready.

How will vaccines work for COVID-19?
How the spike protein is produced
The benefits of different designs
Why boosters may be needed
What determines how we respond to vaccines
Why vaccines provide strong immunity
How to use a vaccine when it’s available

How is the Oxford vaccine being developed, tested and approved?
The many steps of vaccine development
The results of phase 1 and phase 2 trials
How the phase 3 trial will work
Why testing was paused – and why we shouldn’t be alarmed
Why vaccine makers need to be more open
Why we need to know what’s in placebos

How will the vaccine be made and rolled out?
How to prepare enough vaccines for the whole world
How tobacco could play a role in producing a vaccine
Why vaccines need to be kept cold
Will rich countries buy up the supply when vaccines are available?
How to stop rich countries from depriving poorer ones
Who should get a vaccine first?

How do you counter resistance and scepticism?
Vaccine hesitancy is nothing new
Are anti-vaxxers that big a problem?
How the far right is exploiting the pandemic
How to build trust in vaccines

How will vaccines work for COVID-19?

Producing the spike protein

Although the way the body interacts with SARS-CoV-2 isn’t fully understood, there’s one particular part of the virus that’s thought to trigger an immune response – the spike protein, which sticks up on the virus’s surface. Therefore, the two leading COVID-19 vaccines both focus on getting the body to produce these key spike proteins, to train the immune system to recognise them and destroy any viral particles that exhibit them in the future.

The pros and cons of different designs

The leading vaccines both work by delivering a piece of the coronavirus’s genetic material into cells, which instructs the cell to make copies of the spike protein. As Suresh Mahalingam and Adam Taylor explain, one (Moderna’s) makes the delivery using a molecule called messenger RNA, the other (AstraZeneca’s) using a harmless adenovirus. These cutting-edge vaccine designs have their pros and cons, as do traditional methods.

Boosters may be needed

The strongest immune responses, says Sarah Pitt, come from vaccines that contain a live version of what they’re trying to protect against. Because there’s so much we don’t know about SARS-CoV-2, putting a live version of the virus into a vaccine can be risky. Safer methods – such as getting the body to make just the virus’s spike proteins, or delivering a dead version of the virus – will lead to a weaker response that fades over time. But boosters can top this up.

What governs how we respond to vaccines?

A vaccine’s design isn’t the only factor that determines how strong our immune response is. As Menno van Zelm and Paul Gill show, there are four other variables that make each person’s response to a vaccine unique: their age, their genes, lifestyle factors and what previous infections they have been exposed to. It may be that not everyone gets long-lasting immunity from a vaccine.

Why vaccines provide strong immunity

If well-designed, a vaccine can provide better immunity than natural infection, says Maitreyi Shivkumar. This is because vaccines can focus the immune system on targeting recognisable parts of the pathogen (for example the spike protein), can kickstart a stronger response using ingredients called adjuvants, and can be delivered to key parts of the body where an immune response is needed most. For COVID-19, this could be the nose.

How to use a vaccine when it’s available

Scientists think between 50% and 70% of people need to be resistant to the coronavirus to stop it spreading. Using a vaccine to rapidly make that many people immune might be difficult, says Adam Kleczkowski. Vaccines are rarely 100% effective, and hesitancy and potential side effects may make a quick, mass roll-out unrealistic. A better strategy might be to target people most at risk together with those likely to infect many others.

How is the Oxford vaccine being developed, tested and approved?

The many steps of vaccine development

Vaccine development is quicker now than it ever has been, explain Samantha Vanderslott, Andrew Pollard and Tonia Thomas. Researchers can use knowledge from previous vaccines, and in an outbreak more resources are made available. Nevertheless, it’s still a lengthy process, involving research on the virus, testing in animals and clinical trials in humans. Once approved, millions of doses then need to be produced.

Phase 1 and phase 2 trials are successful

After showing promise in animals, the University of Oxford’s vaccine moved onto human testing – known as clinical trials, which are split into three phases. Here, Rebecca Ashfield outlines the joint phase 1 and 2 trial that the vaccine passed through to check that it was safe and elicited an immune response, and explains how the vaccine actually uses a separate virus – a chimpanzee adenovirus – to deliver its content into cells.

How the phase 3 trial works

Earlier trial phases showed that the vaccine stimulated the immune system, as expected. But the million-dollar question is whether this actually protects against COVID-19. Finding out means giving the vaccine to thousands of people who might be exposed to the coronavirus and seeing whether they get sick. As Ashfield and Pedro Folegatti show, this requires running vaccination programmes in countries across the world.

Testing was paused – and that’s OK

In September, the phase 3 trial of the Oxford vaccine was paused after a patient fell ill with a possible adverse reaction. Understandably this caused dismay, but it shouldn’t have, says Simon Kolstoe. Pauses like this are common, as independent moderators are needed to assess exactly what has happened. Often illnesses in trials are unrelated to what’s being tested. But even if they are, that’s exactly what we want these tests to show.

But vaccine makers need to be more open

AstraZeneca didn’t publicly reveal what caused the pause but did share this information with investors. This, says Duncan Matthews, was an example of an attempt to apply old methods of operating to a new situation.

Why we need to know what’s in placebos

A key part of clinical trials are placebos – alternative or inactive treatments that are given to participants for comparison. But a key problem, Jeremy Howick explains, is that some vaccine trials don’t reveal what their placebos contain. Without knowing what benchmark is being used, it’s then difficult for outsiders to understand the relative effect (and side effects) the vaccine has.

How will the vaccine be made and rolled out?

Preparing enough for the whole world

Universal demand for a COVID-19 vaccine means production bottlenecks are a risk. For the Oxford vaccine, production involves growing key components in human embryonic kidney cells, before creating the actual vaccine and then purifying and then concentrating it. Running this process at industrial scale, say Qasim Rafiq and Martina Micheletti, is one of the biggest challenges AstraZeneca faces.

Tobacco – an unexpected ally?

Vaccines contain organic products, which traditionally have been grown using cell cultures in containers called bioreactors. Recently plants have been adapted to function as bioreactors too, which could help production be massively increased. Tobacco may be especially useful: it grows quickly, is farmed all over the world, is leafy and easily modifiable. The tech hasn’t been approved for mass producing medicines – but demand may change that.

Keeping vaccines cool will be crucial

Because COVID-19 vaccines will contain biological material, they’ll need to be kept cold right up until they’re delivered, explains Anna Nagurney. Fail to keep them cool and they’ll become ineffective. Refrigeration will therefore be a major challenge in any roll-out campaign; an estimated 25% of vaccines are spoiled by the time they reach their destination. A potential solution could be to encase their heat-sensitive parts in silica.

‘Vaccine nationalism’ threatens universal access

Some governments are signing agreements with manufacturers to supply them with vaccines ahead of other countries. Poorer nations risk being left empty handed – putting people at risk and preventing any attempt to coordinate suppressing the coronavirus worldwide. It’s also unclear how access is being priced in these deals.

How to counter vaccine nationalism

India can play a key role in avoiding this “richest-takes-all” scenario, says Rory Horner. It’s traditionally been a major supplier of medicines to the global south, and has the capacity to create more vaccines for COVID-19 than any other country in the world. India’s Serum Institute has signed up to make 400 million doses of the Oxford vaccine this year, but with a population of 1.35 billion, how many will go abroad isn’t yet clear.

Who will get the coronavirus vaccine first?

We need to plan now, say Laurence Roope and Philip Clarke. Governments have big decisions to make. The pandemic is akin to a war situation, so there’s an argument these vital goods should be rationed and banned from private sale. Authorities also need to decide who should be prioritised: those most vulnerable, people most likely to spread the virus, or those who can kickstart the economy by returning to work.

How do you counter resistance and scepticism?

Public resistance is a sizeable problem – but nothing new

Surveys show that one in four New Zealanders remain hesitant about a coronavirus vaccine, while one in six British people would refuse one. But vaccine hesitancy has been around for a long time, writes Sally Frampton. And Steven King argues the past – such as when smallpox vaccines were resisted – may provide some solutions to this problem.

Are anti-vaxxers a problem?

Not all hesitancy is the same, says Annamaria Carusi. As well as the hardcore anti-vaxxers, plenty may resist COVID-19 vaccines on safety or animal welfare grounds. Indeed, while anti-vaxxers attract a lot of attention, their influence on vaccination rates is often overstated, argues Samantha Vanderslott. In fact, desire for a vaccine is so widespread and strong that anti-vaxxer positions may be harder to defend right now.

The far right is exploiting the pandemic

A recent report from the United Nations Security Council warned that extreme right-wing groups in the US are using the pandemic to “radicalise, recruit, and inspire plots and attacks”. Blyth Crawford gives a run-down of the major groups at work in America – what their aims are, the methods they’re using to reach people, and the key pieces of misinformation that they’re peddling.

How to build trust in vaccines

The usual strategy is to double down on positive messaging. But a better strategy, Mark Honigsbaum argues, would be to acknowledge that there’s a lot we don’t know about how some vaccines work, but that the benefits of taking vaccines far outweigh the risks. A further step could be to make sure that manufacturers are liable should vaccine recipients suffer negative effects. Often manufacturers are exempt.

Looking ahead

The future is full of possibility. COVID-19, Sars, Mers and the common cold are all caused by coronaviruses, and scientists are considering whether it’s possible to create a vaccine that could offer protection against them all – and perhaps even against an as yet unknown coronavirus we’re yet to encounter. Admittedly, having a vaccine that can do this seems unlikely in the near future.

We shouldn’t get ahead of ourselves, though, says Sarah Pitt. No vaccine has yet completed its safety trials, and we can’t yet be sure that any vaccine will permanently prevent people from catching COVID-19. We need to prepare ourselves for the very real possibility that a COVID-19 vaccine only reduces the severity of symptoms or provides temporary protection.The Conversation

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Let’s block ads! (Why?)

Source link

Continue Reading


Local pharmacist expects huge turnout for the flu vaccine this year – CHAT News Today



To pre-book an appointment, you can call your local pharmacy or fill out the request on their website.

Though some pharmacies are offering walk-ins.

Greg’s Remedy’s Pharmacy says they are offering walk-ins with two dedicated pharmacists giving injections.

Owner Greg Bueckert says they’re expecting a huge turnout this year.

He says people were lined up at 8 AM Monday morning to get their flu vaccine.

“The idea of the influenza shot is to make sure that the hospitals are not overwhelmed with influenza and COVID, so they can dedicate most of the resources to COVID. So we’re encouraging everybody to get a shot this year. Especially high risk,” Bueckert told Chat News.

Chief Medical Officer of Health Dr. Deena Hinshaw also requests that all Albertans get a flu shot.

In her COVID-19 update on Friday and again in a Tweet on Monday, she says getting immunized supports Alberta’s pandemic response.

Last year, nearly 8,500 Albertans contracted the flu and 41 people died.

“Getting immunized is an easy way to protect your health. The flu shot won’t prevent COVID-19 but it will reduce your chances of getting sick with influenza and spreading it to others. Seniors, young children, pregnant women, and those with chronic health conditions are the most at risk of suffering severe and sometimes fatal complications from the flu,” Dr. Hinshaw said.

AHS is offering vaccines through public health clinics for children under 5, plus their family and household members.

Those vaccines are by appointment only and can be booked online.

Let’s block ads! (Why?)

Source link

Continue Reading


Three Toronto hospitals dealing with COVID-19 outbreaks – Toronto Sun



Article content

Three hospitals in Toronto are facing COVID-19 outbreaks, with several patients and staff confirmed to be infected.

St. Joseph’s Health Centre in the west end, as of this morning, has seven active COVID-19 positive patients and 11 active COVID-19 positive staff related to the outbreaks.

The total number of patient cases that tested positive for the virus at the hospital is 14, which includes the seven aforementioned patients as well as another seven unrelated to this outbreak, according to the hospital.

The outbreak stemmed from four units within the hospital — the 2L medicine unit, the 2E unit, the 3M unit and the 4E unit between Oct. 3 and Oct. 16.

“We are managing a significant number of confirmed COVID-19 cases at St. Joseph’s Health Centre,” said spokesperson Jennifer Stranges.

“Our patients, staff and community are our top priority, and we have implemented additional hospital-wide precautions to keep everyone safe.”

According to provincial health guidelines, a COVID-19 outbreak is defined as “at least two cases within a 14-day period where both could reasonably have been acquired” in a congregate setting.

Toronto Western Hospital on Bathurst at Dundas St. W. is pictured on Monday, October 19, 2020. Photo by Jack Boland /Toronto Sun

At Toronto Western Hospital, three patients and six staff members have tested positive for coronavirus.

Since Oct. 15, the outbreak has affected units 8A and 8B of the general internal medicine department in the hospital’s Fell Pavilion.

More On This Topic

According to University Health Network spokesperson Gillian Howard, additional testing of patients and staff is ongoing.

“The only new information is that there are no additional positive tests today from the swabbing that has been underway from Oct. 12 forward, so we remain at three patients and six staff with positive tests which may be hospital-acquired,” Howard said on Monday.

We apologize, but this video has failed to load.

[embedded content]

The Centre for Addiction and Mental Health is also facing an outbreak at its Queen St. W. location after two patients fell ill and tested positive for the virus.

According to its website, the cases are tied to Unit 1-4.

Let’s block ads! (Why?)

Source link

Continue Reading


Struggling Manitoba hotel industry pleads for tax relief from province –



Hotel owners in Manitoba are on edge as heightened pandemic restrictions come into force in Winnipeg and the surrounding area on Monday — and say they need government help to get through this.

“It’s like my worst nightmare ever. The impact is just, I can’t paint a more gloomy picture,” said Manitoba Hotel Association president and CEO Scott Jocelyn.

“It’s been a really tough seven or eight months dealing with all of this, and today we’ll see more challenges for our people. People are on edge. They’re very frustrated and really, really struggling.”

Starting Monday, stand-alone nightclubs, bars and beverage rooms (which are attached to hotels) must close, along with casinos, entertainment facilities with live entertainment, video lottery lounges and bingo halls.

Businesses licensed as restaurants and lounges can stay open but are limited to 50 per cent capacity and can only seat up to five people at a table.

The restrictions will stay in place at least two weeks and come as the Winnipeg region battles the worst surge of COVID-19 cases Manitoba has seen since the pandemic began.

Jocelyn said the provincial government has tried hard to balance the economy and the public’s safety through all of the measures it has instituted since March, “but the reality is, the protocols they’re putting upon us are having a huge impact on what we do.

“If people can’t travel into the city or the province, then we can’t put people in our rooms, we can’t hold events, we can’t have people congregating in our bars, in our restaurants. Everything we do is being impacted.”

Several broad assistance programs for business and individuals have been introduced by the province, but Jocelyn said the hotel association is hoping for specific relief.

Other provinces have better supported their hotel industry, he said.

“That’s one of the frustrations. Some of the things that have happened in other provinces — those provinces have handled them with some sector-specific relief, and the biggest one for us is paying the tax bill,” Jocelyn said. 

A hotel’s taxes are based on revenues, but from two years ago, he explained. 

“There isn’t a hotel in Manitoba that’s doing what they were doing two years ago [in terms of revenues due to COVID-19]. So how do you pay that bill?” Jocelyn said.

“They’ve weathered many storms but not a storm like this, and they really need some relief so they can continue to do all the great things that we do. We work hard for the province, we collect lots of taxes for the province in good times, and we need some help today.”

Jocelyn doesn’t believe the government knows how wounded the industry is, so his organization is just wrapping up a full economic impact study by accounting firm Meyers Norris Penny.

“We really need some numbers that we can put in front of them to paint that picture. I’m anxiously awaiting that report,” he said. He expects it will be released around the second week of November.

While some hotels in the province benefited from Manitobans taking stay-cations this year and exploring more of their own province, it’s not enough to turn the year around, Jocelyn said.

Some of the biggest hotels in Winnipeg have had single-digit occupancy rates after being closed for a few months due to COVID-19, he said.

“The stay-cation model, that’s not going to work for them.”

It’s difficult to remain viable when you’re only filling two out of every 10 rooms, agreed Winnipeg Chamber of Commerce President and CEO Loren Remillard, who echoed Jocelyn’s call for help.

“We need to have measures in place so we can ensure when we do get through this, we have a business community to return to, we have a restaurant sector, we have viable hotels and an arts and culture community that’s still vibrant.”

While there have been hardships across-the-board in the business community since the onset of the pandemic, those sectors have been disproportionately damaged, Remillard said. When the economy reopened in phases through late spring and early summer, they did not see a significant bounce back.

The restaurant, hotels and arts and culture communities have taken a big hit since the pandemic began, says the Winnipeg Chamber of Commerce. (Gary Solilak/CBC)

The restrictions that kicked in Monday will exacerbate an already-precarious situation, he said.

The business community fully understands the need, around public health, to implement those conditions, but it is “frustrating” to not see a corresponding level of relief measures in Manitoba for those hard-hit industries, he said.

For perspective, the Quebec government set aside $100 million to help businesses cover 80 per cent of fixed expenses such as rent and electricity for shuttered bars and restaurants, Remillard noted, adding that Saskatchewan’s government has specific funding streams for hotels, hospitality and the event industry.

Rainbow Stage was one of the many attractions that went quiet due to COVID-19 restrictions. (Kayla Kocian/Rainbow Stage)

On Friday, when the latest restrictions were revealed, Manitoba Health Minister Cameron Friesen said it’s too early to talk about providing financial assistance to businesses impacted by the measures.

Remillard strong disagrees.

“We needed to be talking about this months ago. There is no too soon,” he said. “Two weeks is a lifetime for a business that’s holding on on a day-to-day basis.

“We need government to be a partner with the business community, to say ‘we recognize the difficulty you’re in and that it’s made worse by these necessary public health measures. We’re here to work with you to find solutions to ensure that you remain viable.'”

Let’s block ads! (Why?)

Source link

Continue Reading